MedPath

Validation of a Specific Measure for Assessment of Compliance With Treatment in Patients With Hemophilia

Conditions
Haemophilia
Registration Number
NCT02582450
Lead Sponsor
Real Fundación Victoria Eugenia
Brief Summary

Research project for validation of a questionnaire on compliance to treatment in patients with hemophilia. It is intended to validate the American VERITAS-PRO scale according to the international methodology validation questionnaires: reverse translation, according to intersubject patients, psychometric validation and reliability analysis with large sample of patients.

Detailed Description

The validated questionnaire obtained in this project will identify the actual degree of patient compliance to drug therapy, using as gold standard the difference between the treatment prescribed and administered.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
70
Inclusion Criteria
  • Patients with hemophilia A and B
  • Patients who have previously signed the informed consent document
Exclusion Criteria
  • Patients with other congenital coaghulopatías (eg, Von Willebrand's disease)
  • Patients with cognitive impairment, or oral or written understanding

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Translation of the original questionnaire (English) to Spanish1 day (Screening visit)

Three health experienced in the treatment of hemophilia and knowledge of English, translated into Spanish the HAL and HEP questionnaire. Two native speakers (English and Spanish), reverse-translate the original text of the HAL and HEP questionnaires and the text translated by the Spanish health.

The translated version of the questionnaire1 day (Screening visit)

10 patients with hemophilia adults enrolled randomly will participate in the pilotage.

The clarity of the questions in Spanish translated version and the relevance of each of the items of the questionnaires will be evaluated.

Sending the questionnaire to a large sample of patients for final validation1 day (Screening visit)

70 patients with hemophilia will participate in the pilotage. The validity and reliability of the Spanish version translated from the questionnaires will be assessed.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Real Fundación Victoria Eugenia

🇪🇸

Madrid, Spain

Real Fundación Victoria Eugenia
🇪🇸Madrid, Spain
Rubén Cuesta-Barriuso, PhD
Contact
+34 913146508
ruben.cuestab@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.